
FDA Mandates Eye Condition Warnings for Popular Weight-Loss Drugs
The US Food and Drug Administration (FDA) has ordered manufacturers of GLP-1 medications, widely used for weight loss, to include warnings about a rare eye condition. This condition, nonarteritic anterior ischemic optic neuropathy (NAION), carries a risk of sudden and permanent vision loss. The requirement applies to popular drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound.
10 November 2026 · 1 min read












